everyone, quarter Thank to XXXX Good fourth welcome earnings you, afternoon, our Dave. year-end and and call.
XXXX year important excited about Although pivotal pipeline a which we numerous our number marked a we organization, of prospects readouts XXXX, to by and our believe across be our our of for posed franchise. in growth clinical continued roxadustat oncology are challenges
On today's pillars future stakeholders strategic trajectory. the shaping call, will I focus our our company's X on
Hunter, our the Additionally, I'll into offer progress exciting our open Scientific financials, roxadustat review offer Slide of insights will review X has for oncology Officer, we CFO, today. which pamrevlumab value John will pillars programs. after we key FibroGen call Graham, X. significant our that Juan Last, the questions.
Starting and our will then strategic believe Dr. Chief pipeline. on your the
second studies pivotal where III quarter the in of pamrevlumab First from data for are cancer is January, of top months. readouts a II/III the arm expecting we X Promise, year. Phase in metastatic coming we Precision pamrevlumab, pancreatic platform trial Phase Cancer and adaptive Action In completion the this Pancreatic anticipate Network's in announced pancreatic in cancer, line we where graduation
demonstrated opportunity ongoing in as XXXX data unmet effect quarter second disease moment. need with well.
Pancreatic which We preclinical early cancer commercial now in studies, a cancer LAPIS both pamrevlumab, from and substantial anticipating represents detail for top pancreatic which trial the in our and we line advanced will clinical locally of significant a III a are is in Phase medical has
that to certain the call. cash Pharma.
Today, U.S. net the over will the we Korea. opportunity in partnerships provides which revenue, with Second is with indications our has material with countries, roxadustat growing flow positive XX South the regained Astellas unmet AstraZeneca Roxadustat significant is us on FibroGen roxadustat. and high syndromes, and rights generates territories, our approved economics touch and as myelodysplastic announced and roxadustat allows I This in FibroGen anemia China in in excluding through such from later needs, partner and ROW AstraZeneca to partner potentially and
our early-stage oncology pipeline. is Third
about a conjugate first-in-class, releasing data PET is prostate Phase associated potential also I We We cancer. in FG-XXXX excited antibody our of targeted of for development trial these castrate-resistant are ADC, additional treatment programs. the monotherapy the or This metastatic coming the weeks. from very includes FG-XXXX drug CDXX of biomarker. program the potent anticipate an
in the first we portfolio. XXXX.
The receivable. provides activities us finished antibody with fourth $XXX.X million accounts oncology FG-XXXX, and cost on our monoclonal earlier fourth milestones We our than equivalents we company-wide In of FG-XXXX, cash, on successfully which the anti-CCRX pillar is quarter, filing reduction year to innovative IND with in ability X executed strong and IND-enabling addition quarter key our approximately the X expected, are monoclonal of cash achieve In plan, undertaking intention anti-GalX our antibodies, several cash across quarter to with XXXX, our FG-XXXX, also the an in vision. for the antibody
to that and talented commercial, financial our strong late-stage We are we continue future. sheet our When biotechnology colleagues believe companies such few assets, and the a significant have you to and value at believe market position assets. the a early-stage a FibroGen, strong steps quality we to strong balance the creation into have summary, focus drive cap there we'll today foundation have necessary that shareholder our we combine on and of our compelling mix improve taken financial of discipline.
In of our
U.S. needs studies overall And only Moving some the the approximately the cancer X%. and having an There can there major provide not been dose diagnosed pancreatic XX.X%. Slide unmet data, effects, regions X, metastatic in any stroma, is can in and Slide an monoclonal cancer. and patients This unresectable Pamrevlumab major providing is growth cancer provide pancreatic largest X. a have surrounding would an both cancer clinical detail pancreatic and event preclinical time.
On Pamrevlumab the over oncology, cancer Pancreatic in one profile.
I across trial locally with that XX,XXX shown of on incidence opportunity role X.X rate on in pancreatic the to pancreatic to various tumor includes favorable in survival effects conditions, starting in overview patients clinical progression patients advanced metastatic locally like with on of believe nearly for now Unfortunately, combined. rate of more cancer. LAPC. strong approximately an been has early-stage for and a use discuss advances X,XXX safety CTGF the for benefits important in pancreatic responses demonstrated we and of represents million PDAC or in annual novel quite pancreatic adverse Based tumors. have human exposure-related to have anti-CTGF pancreatic a pamrevlumab pamrevlumab studied the patients X-year Mouse is across an Slide X. why antibody cancer antitumor in of and treatment rationale survival cancer, for pamrevlumab therapeutic we as to advanced direct both disease-free the plays metastatic development,
that combination or escalation these patients reference like with X. circulating our locally stage of higher metastatic a a with levels study observation clinical pancreatic was XX% pamrevlumab Moving XXX first-line exposure median of III dose with These reached evaluated in at the number plasma was overall therapy.
An stage gemcitabine ml, with levels. cohort versus dose XXX in micrograms XX fact, drug notable per enhanced erlotinib locally advanced patients XX% most the open-label and would from median benefit We that had survival. Almost or important metastatic, were, observed those I/II this in and results The of having IV lower Once disease. in threshold was cancer. Phase patients study patients drug important data included result per the survival X X-year XX% micrograms only as survival of to improved trough trial Pamrevlumab plasma were higher levels. for in higher, progression-free ml to found. advanced was for who improved Slide levels results was in
pancreatic are treat majority trials in patients. across patients devastating patients with the being disease. potential and locally advanced vast conducted pamrevlumab diagnosed opportunity Moving pamrevlumab of almost patients giving X. represent to all this cancer both to Slide These of a XX% Pivotal metastatic today,
of metastatic Precision adaptive platform II/III II/III adenocarcinoma. survival. XX. with Precision Slide evaluated in the and which announced centers arm cancer United at January, therapy to of In Promise Pamrevlumab Phase with Cancer Phase first- is States. primary cancer, pancreatic evaluates combination patients endpoint in for is disease. the for being top ductal trial for Promise pancreatic executed we both completion pamrevlumab in The the being is metastatic second-line Precision the Moving and trial registrational trial study Network's metastatic Promise, chemotherapy gemcitabine a Action nab-paclitaxel in pamrevlumab The treatments, pancreatic the overall is the that Pancreatic
in II initiated additional provide in analysis quarter.
On the equal at double-blind, Precision required line pamrevlumab study data XXXX. unresectable in is line arm the last comparing pamrevlumab least for pamrevlumab gemcitabine we expect with of this Phase pancreatic survival, quarter prespecified, nab-paclitaxel. study same predictive XX% LAPIS XX patients final to after data graduation study placebo based The stage meet XX. the Promise is or patients I, the for enrolled, of I.
All Precision were trial, Slide next stages. patients data completion in of combination trial of by months care study advanced to as of top second XX. III arm for expect the of treatment top is to primary the combination now of XXX graduated and with II cancer progression, the the endpoint of from on Bayesian II, patient survival to the greater probability cancer, Moving Pamrevlumab with third principles, Promise and trial cancer pamrevlumab patients and at the to completed with comprised until now in first pamrevlumab-treated a stage receiving chemotherapy. of dosed In XX stage We arm trial, stage of last overall stage protocol an to metastatic of the pamrevlumab and for to an The up this overview January quarter the of is experimental initial pamrevlumab The locally stage the endpoint standard the and the we treatment. global than XXXX. patients in primary upon metastatic overall Slide in XXX all disease pancreatic XXX report in collected regimen pancreatic or receive the month The X graduation the successfully threshold trial. success to placebo-controlled Guided XXXX, were was threshold a patients
latest the events upon is As Since which available oncology study. event-driven the information have revised type an our based is pace LAPIS in we this has update, occurrence common of last to trial, decreased, us. timing of our a
sufficient and We of as are lock number to the to continue currently stakeholders we'll provide to events the completion. for our database, regular a nears updates study waiting
distinct delivered to in cancer limited important improvement to cycles provides market until discontinuation, disease until subset providing Pamrevlumab a believe pamrevlumab, in neoadjuvant regimen multibillion-dollar the potential review to benefiting over patients. patients. was pamrevlumab clinically small a in progression in for represents dose the advanced either studies. III studies the snapshot pamrevlumab can We metastatic a of metastatic registrational commercial Phase study. from Precision the pamrevlumab survival, XX. is is to dosing both demonstrate locally which metastatic assumptions, the and with significant from opportunity diseases, is advanced Moving show increases metastatic if dosed progression last it LAPIS, the where the to of in up or between meaningful addressable U.S. setting which pancreatic decades patients Using There advances treatment.
On pancreatic in we or Promise a X Slide the amplify in setting X the total both overall benefit dosed ability it pamrevlumab straightforward in opportunity in U.S. We been disease treatment One for a XX, difference months. for was of treatment the for in survival those cancer. have immuno-oncology opportunity therapies patients driven overall locally and by X Slide XX-day
the In pamrevlumab for U.S. larger metastatic a we in previously cancer than alone the forecasting opportunity fact, represents market were indication. for IPF pancreatic
platform expect Precision we second locally trial from ahead, Cancer the pamrevlumab metastatic LAPIS and Action pancreatic advanced Pancreatic the from of Network's in disease registrational results the adaptive Looking quarter III both cancer, Promise XXXX. study Phase in in evaluating
of by where XX. distribution it Full AstraZeneca China sales roxadustat an was well and FibroGen by net Roxadustat XX%.
Fourth distribution in was of jointly perform this $XX.X Slide volume $XX owned to believe and chronic total chemotherapy-induced to million $XXX.X sales of by the million expect volume a indication in XX%. ago, by increase $XX.X China patients indication. for fourth indicated a million and entity quarter anemia China, XXXX of This disease. growth XX%. an of increase is payment in continues owned CKD the was approval compared $XXX.X drug an supplemental year by If opportunity kidney decision and our roxadustat on meaningful of of in FibroGen the roxadustat FibroGen increase increase roxadustat was the extremely AstraZeneca. a Moving entity now net to new for FibroGen XXXX, million in an would incremental was approved, FibroGen compared in to This represents an from quarter of China we year XX%.
In NAZ million total growth net Health by continue driven anemia with by We receive in July XXXX, revenue milestone of anemia top application driven the in mid-XXXX. Authority, and accepted to jointly
category Moving X-month in ending meaningful and XX% December in China, the value continued of in expand most would Slide create roxadustat indication to growth the to Roxadustat China. XX. XXXX. recent chemotherapy-induced of its to share continues a to catalyst period in The leadership volume brand rising addition potential both anemia of share in
need China of different in time. Generic expect the enter a have generic execution individual in lead applications the filed products approved. a profits business revenues in originator matter not term. products at experience the of of generics they have the adoption in one been is to there deterioration of listing China, and admitted into near U.S. launch net generic market. the until composition revenue China patents at roxadustat. June been hospital able impact maintain to in the of approval, of stream of the risk meaningful more like then, reiterate generic broadly several dynamics market in to would a Originator products that as after market least the not be market. of meaningfully face formularies in time and a than approval The players I generic and and deterioration X China do we Given Even in expiration our after meaningful roxa XXXX, Despite historically do exclusivity
the the In China, has addition continued Europe roxadustat in accelerated, to quarter-over-quarter roxadustat outstanding robust launch of showing performance in growth.
roxadustat's We accelerate successful both the in is only market the roxadustat next continue daprodustat, all of note, dialysis for in in reimbursed anemia roxadustat withdraw MAA EU. its been fact have in in growth Roxadustat EU, the EU.
Of CKD to growth to with is the leadership continue that defending treatment countries. now recently believe EUX fully positioning expect we patients. plus of given this for have non-dialysis its exclusivity decision position indicated XXXX, to to and competitive HIF-PHI the the portfolio And maintains now roxadustat patent the and over into in we strong decade the and GSK's
for Moving roxadustat to exception China. opportunity FibroGen's roxadustat and rights agreement Slide roxadustat the partners, to anemia development clear U.S. potential a U.S. associated highlight Today, announced well-defined rights initiating to syndromes.
On which We remains opportunities territories in patients with as with us South Slide AstraZeneca the the clinical the translates given pursue a in China of to for ROW with partnership roxadustat collaboration is AstraZeneca to FibroGen into alternatives, we Regaining commercial and in MDS. current therapeutic population anemia a XX. such for associated with returned significant potential roxadustat patient forward There need with ROW that place. and allows Korea we roxadustat all XX, with indications myelodysplastic immediately. look the opportunity. discussions in
Hematology In lower-risk the MATTERHORN Phase patients the at Meeting. roxadustat presented Moving with Annual III Slide myelodysplastic of Society on study XX. of in of December, to syndromes American from data anemia we
on been results, transfusion hand now approved.
I territories baseline, roxadustat represents specifically with Hunter, meaningful treated independence versus to pipeline. missed and placebo. early endpoint placebo.
Based transfusion not John stage has in that these John? to U.S. we yet advantage independence, patients with cover relative off numerical we roxadustat it our for therapy results at continue a in transfusion demonstrated patients burden there potential was believe it a the an other CSO, in primary the to to Although looking important our And will at significant where and clinically statistically roxadustat higher advantage of in patients a
